Shanghai Haohai Biological Technology Co., Ltd. (HAOHAI BIOTEC) has issued its proxy form and notice for the 2025 Annual General Meeting, set for 2:00 p.m. on Friday, 29 May 2026 at 24/F, WenGuang Plaza, No. 1386 Hongqiao Road, Changning District, Shanghai. Key matters requiring shareholder approval are as follows:
1. Routine Business • Board Work Report for 2025 • 2025 Financial Report • 2025 Profit Distribution Plan and authorisation for the Board to declare 2026 interim dividends • Appointment of external auditors for the 2026 financial statements and internal controls
2. Remuneration and Governance • 2026 remuneration plan for directors • Updated Remuneration Management Policies covering directors and senior management
3. Board Composition • Election of Ms. Tian Min as an executive director • Election of three independent non-executive directors—Mr. Chan Sui Yu, Mr. Song Yuanyang and Ms. Xu Duoqi—via cumulative voting
4. Capital Management • Special resolution granting the Board a general mandate to repurchase H shares
Shareholders recorded in the H-share register may appoint proxies by submitting completed forms to the company’s registrar, Computershare Hong Kong Investor Services Limited, by 2:00 p.m. on 28 May 2026. Attendance in person remains an option, in which case previously lodged proxies will be deemed revoked.